Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00026286 · ClinicalTrials.gov registry record · Phase 3

Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer

A Phase 3 study, sponsored by Eastern Cooperative Oncology Group.

Completed
Registry status
Phase 3
Development phase

NCT00026286 is a Phase 3 study that has completed, run by Eastern Cooperative Oncology Group.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00026286, a Phase 3 study, has completed, sponsored by Eastern Cooperative Oncology Group.

COMPLETED
Registry status
Phase 3
Development phase

Study Summary

RATIONALE: Hormone replacement therapy may be effective in managing the hot flashes and/or vaginal symptoms in postmenopausal women who are receiving tamoxifen for breast cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of hormone replacement therapy in managing hot flashes and/or vaginal symptoms in postmenopausal women who are receiving tamoxifen for breast cancer.

Interventions

  • DRUG medroxyprogesterone
  • DRUG conjugated estrogens

Trial Details

FieldValue
Start Date 2000-11-28
Est. Completion 2007-06-15
Phase Phase 3

Sponsor

Eastern Cooperative Oncology Group

141 total trials

What the Registry Record Tells You About NCT00026286

The ClinicalTrials.gov registry entry for NCT00026286 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which medroxyprogesterone is the first listed.

NCT00026286 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00026286 about?

NCT00026286 is a clinical study titled "Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer". RATIONALE: Hormone replacement therapy may be effective in managing the hot flashes and/or vaginal symptoms in postmenopausal women who are receiving tamoxifen for breast cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of hormone replacement therapy in managing hot flashe...

What is the current status of trial NCT00026286?

This trial is currently completed. It is a Phase 3 study. The study started on 2000-11-28. Estimated completion is 2007-06-15.

What interventions are being tested in trial NCT00026286?

The interventions under investigation include: medroxyprogesterone (DRUG), conjugated estrogens (DRUG).

Who is sponsoring clinical trial NCT00026286?

This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.